MedTrace Logo

Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients

NCT04341207 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2020-04-10

No results posted yet for this study

Summary

To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).

To evaluate the Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).

Conditions

  • Cancer & COVID 19

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 200 mg 3 times a day for 10 days

DRUG

Azithromycin

Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-03
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341207 on ClinicalTrials.gov